Posts Tagged ‘drugtarget’
Data Generation Project-CM4AI – BRIDGE2AI
October 4, 2026Can an AI-designed drug slow aging?
September 28, 2026https://ctrk.klclick.com/l/01M2ZDVD112D4GPK2S1Z8EH3BR_23
QT:{{”
Elysium Abstract
…
An AI-designed drug sent six aging clocks backward
In a 12-week phase 2a trial, an AI-designed drug for idiopathic pulmonary fibrosis reduced predicted biological age across six protein-based aging clocks in 42 participants. The findings don’t prove the drug slows aging, but they point to a new way to study it. “This is one of the few concrete examples of a drug largely designed with generative AI,” says Mark Gerstein, Ph.D., Albert L. Williams Professor of Biomedical Informatics at Yale and a member of Elysium’s Scientific Advisory Board. “Moreover, it’s impressive to see how AI was used throughout the whole drug-development process, from upstream target finding to analyzing the downstream trial for results related to longevity.” He adds: “This last use has great promise for aging research, showing how conventional disease trials can be made into dual-purpose designs suitable for studying longevity.” (Nature Biotechnology)
“}}
How autoimmune conditions can unexpectedly drive mental illness | New Scientist
September 27, 2026The brain on fire
A link between autoimmune diseases and conditions like schizophrenia, dementia and OCD is prompting a revolution in how we think about mental illness, finds Jamie Ducharme
Brain-on-Fire-article-in-labdropbox–2026-08-30 22.41.05.jpg (30 Aug) + 2nd image
Suggesting an overlap betw. autoimmune & mental diseases
QT:{{“…that she had biomarkers suggestive of the autoimmune disease lupus, though she didn’t have the condition’s hallmark symptoms. Even though the researchers didn’t know exactly what condition the woman had, they treated her with drugs that dampen the immune system, and it worked. After years spent in a near-catatonic state, she began to recover within months of starting the immune therapies.
“}}
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models – PMC
September 26, 2026https://pmc.ncbi.nlm.nih.gov/articles/PMC11738990/
QT:{{”
Using AI-driven methodology, we generated INS018_055, a small-molecule TNIK inhibitor, which exhibits desirable drug-like properties and anti-fibrotic activity across different organs in vivo through oral, inhaled or topical administration…. Its safety and tolerability as well as pharmacokinetics were validated in a randomized,
double-blinded, placebo-controlled phase I clinical trial
(NCT05154240) involving 78 healthy participants.
“}}
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., Aladinskiy, V., Ivanenkov, Y., Polykovskiy, D., Fu, Y., Babin, E., Qiao, J., Liang, X., Mou, Z., Wang, H., . . . Zhavoronkov, A. (2024). A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology, 43(1), 63–75.
https://doi.org/10.1038/s41587-024-02143-0
US govt suspends access to Fable 5 and Mythos 5
June 13, 2026https://www.anthropic.com/news/fable-mythos-access
Statement on the US government directive to suspend access to Fable 5 and Mythos 5
anthropic.com
Ketamine for treatment-resistant depression: When and where is it safe? – Harvard Health
June 10, 2026Teams of AI agents boost speed of research
May 29, 2026https://www.nature.com/articles/d41586-026-01596-4
QT:{{” In one experiment, Natarajan and his colleagues used Google’s Co-Scientist to look for approved drugs that could be repurposed to treat a form of blood cancer called acute myeloid leukaemia1. The system identified a list of candidate drugs, from which human researchers selected five for further study. Three of these showed promise in preliminary studies on cells grown in the lab.
FutureHouse, a non-profit AI research lab in San Francisco,
California, developed the second system, called Robin, and instructed it to find drugs to treat an eye condition called dry age-related macular degeneration2. “}}
Gottweis, J. et al. Nature https://doi.org/10.1038/s41586-026-10644-y (2026).
Ghareeb, A. E. et al. Nature https://doi.org/10.1038/s41586-026-10652-y (2026).
FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis | FDA
May 28, 2026https://www.fda.gov/drugs/drug-safety-communications/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug QT:{{” We continue to receive reports of mental health side effects reported with montelukast use. Consistent with our prior evaluations, a wide variety of mental health side effects have been reported, including completed suicides. Some occurred during montelukast treatment and resolved after stopping the medicine. Other reports indicated that mental health side effects developed or continued after stopping montelukast. The Sentinel study, which studied asthma patients 6 years and older, and other observational studies did not find an increased risk of mental health side effects with montelukast compared to inhaled corticosteroids (ICS). However, the Sentinel study and the observational studies had some limitations which may affect how we interpret the results. We also reviewed animal studies, which showed that montelukast given orally reaches the brain in rats.1 (See Data Summary for more information) “}}
Diphenhydramine-induced toxic psychosis – PubMed
May 28, 2026https://pubmed.ncbi.nlm.nih.gov/3718632/
QT:{{” A 24-year-old man presented to the emergency department with acute anticholinergic symptoms, hallucinations, and bizarre behavior following a large ingestion of diphenhydramine (Benadryl). “}}
benadryl can cross BBB & cause delusions
NYTimes: 6 Common Medications That May Lower Your Dementia Risk
May 3, 2026the opposite of bad side effects – “side benefits.”
https://www.nytimes.com/2026/04/17/well/mind/medications-dementia-risk-decrease.html?smid=nytcore-ios-share
